Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.

被引：24

作者：

Harding, James J. ^{[1
]}

Cleary, James M. ^{[2
]}

Quinn, David I. ^{[3
]}

Brana, Irene ^{[4
]}

Moreno, Victor ^{[5
]}

Borad, Mitesh J. ^{[6
]}

Loi, Sherene ^{[7
]}

Spanggaard, Iben ^{[8
]}

Park, Haeseong ^{[9
]}

Ford, James M. ^{[10
]}

Arnedos, Monica ^{[11
]}

Stemmer, Salomon M. ^{[12
]}

De La Fouchardiere, Christelle ^{[13
]}

Ramirez, Santiago Viteri ^{[14
]}

Fountzilas, Christos ^{[15
]}

Zhang Jie ^{[16
]}

Xu Feng ^{[16
]}

Lalani, Alshad S. ^{[16
]}

Piha-Paul, Sarina Anne ^{[17
]}

Abou-Alfa, Ghassan K. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Dana Faber Canc Inst, Boston, MA USA

[3] USC Norris Canc Hosp, Los Angeles, CA USA

[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[5] Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain

[6] Mayo Clin, Scottsdale, AZ USA

[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[8] Univ Hosp Copenhagen, Rigshosp, Copenhagen, Denmark

[9] Washington Univ, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA

[10] Stanford Canc Inst, Stanford, CA USA

[11] Gustave Roussy Canc Campus, Villejuif, France

[12] Rabin Med Ctr, Res Inst Oncol, Davidoff Ctr, Tel Aviv, Israel

[13] Ctr Leon Berard, Lyon, France

[14] Quiron Dexeus, Barcelona, Spain

[15] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[16] Puma Biotechnol Inc, Los Angeles, CA USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.320

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

320

引用

页数：3